Acute lymphoblastic leukaemia develops in both children and adults, with a peak incidence
between 1 year and 4 years. Most acute lymphoblastic leukaemia arises in healthy …

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic malignancy
characterized by aberrant proliferation of immature thymocytes. Despite an overall survival …

Background Relationships between microbiota composition and clinical outcomes after
allogeneic hematopoietic-cell transplantation have been described in single-center studies …

Many hematologic malignancies are not curable with chemotherapy and require novel
therapeutic approaches. Chimeric antigen receptor (CAR) T-cell therapy is 1 such approach …

T cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of immature T
lymphocytes, associated with higher rates of induction failure compared with those in B cell …

Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a distinct subtype of T
lymphoblastic leukemia (T-ALL) identified in 2009, due to its unique immunophenotypic and …

Acute lymphoblastic leukemia (ALL) is the most common malignant disease affecting
children. Although therapeutic strategies have improved, T-cell acute lymphoblastic …

The treatment of acute lymphoblastic leukemia (ALL) has dramatically changed over the
past three decades. However, relapsed and/or refractory ALL still remains with a very low …

Nelarabine, an antimetabolite prodrug, is approved as monotherapy for children and adults
with relapsed and refractory T-cell acute lymphoblastic leukemia and lymphoma (R/R T …

Simple Summary Studies conducted in a recent decade revealed that acute lymphoblastic
leukemia cells exploit various mechanisms to avoid immune recognition and destruction by …